BioSpace News Archive

Orthofix Medical Inc., a global medical device company focused on musculoskeletal healing products, announced the U.S. Food and Drug Administration 510 clearance and the first patient implants of the FIREBIRD™ SI Fusion System.

Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid technology, announced that it has been added to the Russell 2000® index.

Kiniksa Pharmaceuticals, Ltd. reported positive data from RHAPSODY, a pivotal Phase 3 trial of rilonacept, a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha and interleukin-1 beta signaling, in recurrent pericarditis.

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2020 financial results will be reported after the market closes on Monday, August 10. Management will host a conference call at 5:00 p.m. Eastern Time on Au

XOMA Corporation (Nasdaq: XOMA) today announced the Company has been added to the Russell 2000 ® and Russell 3000 ® Indexes following the annual reconstitution, which took effect after the U.S. market closed on June 26, 2020. “We expect XOMA’s addition to these Russell indexes will enhance the Company’s visibility in the investment community and broaden our shareholder base,” stated Jim Neal, Chief Executive Officer of XOMA. The Russe

Harrow Health, Inc. announced that it is set to join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens this morning, according to a preliminary list of additions posted June 5.

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into an agreement to acquire Albany, New York based Engineered Molding Technology (“EMT”), an innovator and manufacturer of single-use silicone assemblies and components used in the manufacturing of biologic drugs. EMT’s standard and custom molded and over-molded connectors and silicone tubing products

Based on compelling proof-of-biology for anti-FcRn agents in Myasthenia Gravis (MG), Immunovant has begun preparations to initiate a Phase 3 registrational trial of IMVT-1401 in MG IMVT-1401’s development program is entirely based on a subcutaneous injection format Cash balance as of June 29, 2020, is approximately $280.4 million NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patie

Cytocom, Inc. (Cytocom), a private clinical-stage biopharmaceutical company developing novel immune modulating therapies targeting cancer, autoimmune, inflammatory, and infectious diseases based on proprietary platforms, announced today the successful completion of a Type B pre-IND meeting with the U.S. Food and Drug Administrati

Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first regulatory approval of vadad